Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.

Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C.

EMBO Mol Med. 2017 Aug;9(8):1011-1029. doi: 10.15252/emmm.201607156.

2.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

3.

MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.

Asundi J, Lacap JA, Clark S, Nannini M, Roth L, Polakis P.

Mol Cancer Ther. 2014 Jun;13(6):1599-610. doi: 10.1158/1535-7163.MCT-13-0446. Epub 2014 Mar 20.

4.

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA.

Cancer Discov. 2014 Jul;4(7):816-27. doi: 10.1158/2159-8290.CD-13-0424. Epub 2014 Apr 25.

5.

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4321-6. doi: 10.1073/pnas.1205575110. Epub 2013 Feb 27.

6.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI.

Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15.

PMID:
29334371
7.

Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.

Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK.

J Clin Invest. 2014 Mar;124(3):1406-17. doi: 10.1172/JCI70454. Epub 2014 Feb 24.

8.

MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.

Aida S, Sonobe Y, Tanimura H, Oikawa N, Yuhki M, Sakamoto H, Mizuno T.

Cancer Lett. 2017 Nov 28;409:116-124. doi: 10.1016/j.canlet.2017.09.008. Epub 2017 Sep 18.

PMID:
28923400
9.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

10.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

11.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2013 Mar;123(3):1371-81. doi: 10.1172/JCI66236. Epub 2013 Feb 1. Erratum in: J Clin Invest. 2013 Jul 1;123(7):3182. J Clin Invest. 2016 Jan;126(1):402-3.

12.

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, Niessen HWM, Rozeman EA, Geukes Foppen MH, Blank CU, Peeper DS.

Nature. 2017 Oct 12;550(7675):270-274. doi: 10.1038/nature24037. Epub 2017 Oct 4.

13.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.

Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.

14.

Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.

Kundu A, Quirit JG, Khouri MG, Firestone GL.

Mol Carcinog. 2017 Jan;56(1):49-61. doi: 10.1002/mc.22472. Epub 2016 Feb 15.

15.

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.

Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.

PMID:
26790143
16.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

17.

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.

Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C.

Pigment Cell Melanoma Res. 2019 Mar;32(2):280-291. doi: 10.1111/pcmr.12741. Epub 2018 Oct 19.

18.

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.

Sensi M, Catani M, Castellano G, Nicolini G, Alciato F, Tragni G, De Santis G, Bersani I, Avanzi G, Tomassetti A, Canevari S, Anichini A.

J Invest Dermatol. 2011 Dec;131(12):2448-57. doi: 10.1038/jid.2011.218. Epub 2011 Jul 28.

19.

Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.

Kozar I, Cesi G, Margue C, Philippidou D, Kreis S.

Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt B):2980-2992. doi: 10.1016/j.bbagen.2017.04.005. Epub 2017 Apr 10.

PMID:
28408301
20.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R.

Ann Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6.

Supplemental Content

Support Center